Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature

References

• Aithal, A., et al., 2018. MUC16 as a novel target for cancer therapy. Expert opinion on therapeutic targets, 22 (8), 675–686.
   PubMed Web of Science ®Google Scholar
• Balduzzi, S., Rücker, G., and Schwarzer, G., 2019. How to perform a meta-analysis with R: a practical tutorial. Evidence-based mental health, 22 (4), 153–160.
   PubMed Web of Science ®Google Scholar
• Bottoni, P. and Scatena, R., 2015. The role of CA 125 as tumor marker: biochemical and clinical aspects. Advances in experimental medicine and biology, 867, 229–244.
   PubMed Web of Science ®Google Scholar
• Chan, A., et al., 2014. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clinical cancer research, 20 (22), 5787–5795.
   PubMed Web of Science ®Google Scholar
• Core Team, R., 2019. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
   Google Scholar
• Cwik, G., et al., 2006. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Archives of surgery (Chicago, IL:1960), 141 (10), 968–973.
   PubMedGoogle Scholar
• Dalton, J.E., Bolen, S.D., and Mascha, E.J., 2016. Publication bias: the elephant in the review. Anesthesia and analgesia, 123 (4), 812–813.
   PubMed Web of Science ®Google Scholar
• Das, S., et al., 2015. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget, 6 (8), 5772–5787.
   PubMedGoogle Scholar
• Dinnes, J., et al., 2016. The Moses-Littenberg meta-analytical method generates systematic differences in test accuracy compared to hierarchical meta-analytical models. Journal of clinical epidemiology, 80, 77–87.
   PubMed Web of Science ®Google Scholar
• Dochez, V., et al., 2019. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Journal of ovarian research, 12 (1), 28.
   PubMedGoogle Scholar
• Doebler, P., 2019. Mada: meta-analysis of diagnostic accuracy. R package version 0.5.9. Available from: https://CRAN.R-project.org/package=mada
   Google Scholar
• Doebler, P., Holling, H., and Böhning, D., 2012. A mixed model approach to meta-analysis of diagnostic studies with binary test outcome. Psychological methods, 17 (3), 418–436.
   PubMed Web of Science ®Google Scholar
• Ducreux, M., et al., 2015. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 26 (Suppl. 5), v56–v68.
   PubMed Web of Science ®Google Scholar
• Duraker, N., et al., 2007. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. Journal of surgical oncology, 95 (2), 142–147.
   PubMed Web of Science ®Google Scholar
• Garg, G., et al., 2014. Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. BMC cancer, 14, 35.
   PubMed Web of Science ®Google Scholar
• Gerritsen, A., et al., 2014. Preoperative characteristics of patients with presumed pancreatic cancer but ultimately benign disease: a multicenter series of 344 pancreatoduodenectomies. Annals of surgical oncology, 21 (12), 3999–4006.
   PubMed Web of Science ®Google Scholar
• Gerritsen, A., et al., 2015. Diagnostic value of a pancreatic mass on computed tomography in patients undergoing pancreatoduodenectomy for presumed pancreatic cancer. Surgery, 158 (1), 173–182.
   PubMed Web of Science ®Google Scholar
• Goh, S.K., et al., 2017. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ journal of surgery, 87 (12), 987–992.
   PubMed Web of Science ®Google Scholar
• Gomes, R.M., et al., 2016. Unexpected benign histopathology after pancreatoduodenectomy for presumed malignancy: accepting the inevitable. Langenbeck's archives of surgery, 401 (2), 169–179.
   PubMed Web of Science ®Google Scholar
• Gu, Y.-L., et al., 2015. Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. Asian Pacific journal of cancer prevention, 16 (15), 6569–6573.
   PubMedGoogle Scholar
• Haglund, C., 1986. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. British journal of cancer, 54 (6), 897–901.
   PubMed Web of Science ®Google Scholar
• Hogendorf, P., et al., 2017. A panel of CA19-9, Ca125, and Ca15-3 as the enhanced test for the differential diagnosis of the pancreatic lesion. Disease markers, 2017, 8629712.
   PubMed Web of Science ®Google Scholar
• Hogendorf, P., et al., 2018. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. Cancer biomarkers, 21 (3), 505–511.
   PubMed Web of Science ®Google Scholar
• Huang, Z. and Liu, F., 2014. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour biology, 35 (8), 7459–7465.
   PubMed Web of Science ®Google Scholar
• Kennedy, T., et al., 2006. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. The American journal of surgery, 191 (3), 437–441.
   PubMed Web of Science ®Google Scholar
• Lee, J., et al., 2015. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—Part II. Statistical methods of meta-analysis. Korean journal of radiology, 16 (6), 1188–1196.
   PubMed Web of Science ®Google Scholar
• Leeflang, M.M., 2014. Systematic reviews and meta-analyses of diagnostic test accuracy. Clinical microbiology and infection, 20 (2), 105–113.
   PubMed Web of Science ®Google Scholar
• Leeflang, M.M., Bossuyt, P.M., and Irwig, L., 2009. Diagnostic test accuracy may vary with prevalence: implications for evidence-based diagnosis. Journal of clinical epidemiology, 62 (1), 5–12.
   PubMed Web of Science ®Google Scholar
• Leeflang, M.M., et al., 2013. Variation of a test's sensitivity and specificity with disease prevalence. Canadian medical association journal, 185 (11), E537–E544.
   PubMed Web of Science ®Google Scholar
• Liu, L., et al., 2016. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Oncotarget, 7 (5), 5943–5956.
   PubMedGoogle Scholar
• Liu, Q., et al., 2016. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis. Oncotarget, 7 (24), 36800–36813.
   PubMedGoogle Scholar
• Moher, D., et al., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine, 6 (7), e1000097.
   PubMed Web of Science ®Google Scholar
• Nishio, K., et al., 2017. Preoperative predictors for early recurrence of resectable pancreatic cancer. World journal of surgical oncology, 15 (1), 16.
   PubMedGoogle Scholar
• O'Brien, D.P., et al., 2015. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clinical cancer research, 21 (3), 622–631.
   PubMed Web of Science ®Google Scholar
• Rawla, P., Sunkara, T., and Gaduputi, V., 2019. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World journal of oncology, 10 (1), 10–27.
   PubMedGoogle Scholar
• Reitsma, J.B., et al., 2005. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of clinical epidemiology, 58 (10), 982–990.
   PubMed Web of Science ®Google Scholar
• Sakamoto, K., et al., 1987. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut, 28 (3), 323–329.
   PubMed Web of Science ®Google Scholar
• Scarà, S., Bottoni, P., and Scatena, R.C., 2015. CA 19-9: biochemical and clinical aspects. Advances in experimental medicine and biology, 867, 247–260.
   PubMed Web of Science ®Google Scholar
• Takwoingi, Y., et al., 2017. Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. Statistical methods in medical research, 26 (4), 1896–1911.
   PubMed Web of Science ®Google Scholar
• Toft, J., et al., 2017. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: a systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. European journal of radiology, 92, 17–23.
   PubMed Web of Science ®Google Scholar
• van Heerde, M.J., et al., 2012. Prevalence of autoimmune pancreatitis and other benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Digestive diseases and sciences, 57 (9), 2458–2465.
   PubMed Web of Science ®Google Scholar
• Wang, Z. and Tian, Y.P., 2014. Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma. Molecular and clinical oncology, 2 (2), 265–268.
   PubMedGoogle Scholar
• Whiting, P.F., et al., 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine, 155 (8), 529–536.
   PubMed Web of Science ®Google Scholar
• Xu, H.X., et al., 2017. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery, 161 (2), 373–384.
   PubMed Web of Science ®Google Scholar
• Xu, H.X., et al., 2018. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma. Pancreatology, 18 (6), 671–677.
   PubMed Web of Science ®Google Scholar